Which type of evidence is most useful for identifying rare adverse effects after widespread drug use?

• A. Randomized controlled trial data
• B. Observational data
• C. In vitro data
• D. Animal data

Answer: (B)

Identifying rare adverse effects after a drug is widely used relies on real-world, large-scale data collected outside the controlled setting of a trial. Randomized controlled trials are excellent for establishing efficacy and detecting common safety issues, but they are typically too small or too short to observe events that occur infrequently. Observational data from post-marketing surveillance and pharmacovigilance systems gather reports from diverse patients across real-world clinical practice, making it possible to spot signals of rare adverse events as usage expands. This approach includes spontaneous reporting, cohort and case-control studies, and active safety monitoring, which together help estimate incidence and explore risk factors in the actual population. In vitro and animal data are useful for understanding mechanisms, but they don’t reliably predict rare adverse effects in humans after widespread use.